Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICM: PD-1 + IL-2 + CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06884670Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, aldesleukin in rectal cancer, sponsored by Jiangsu Provincial People's Hospital. Started Aug 2024; status: completed.
02
Drugs
tislelizumabaldesleukin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06884670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884670.